arrow
N

Niu, Ting

institute of hematology & blood diseases hospital - cams
H指数:0
被引数:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The modified melphalan and busulfan-based regimen combined with maintenance therapy improved the survival of patients with refractory/relapsed AML after allogeneic transplantation: middle-term outcome of a multicenter trial
2024-01-010
PRE
Impact of a novel prognostic model on allogeneic hematopoietic stem cell transplantation outcomes in patients with CMML
2023-06-273
PRE
Dose tapering to withdrawal stage and long-term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: Results from an open-label extension study

剂量逐渐减少至停药阶段以及hetrombopag治疗免疫性血小板减少症的长期疗效和安全性: 一项开放标签扩展研究的结果

2022-03-018
OAAI
Basiliximab for steroid-refractory acute graft-versus-host disease: A real-world analysis
2022-02-0433
PRE
Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of BCR-ABL-Induced B-Cell Acute Lymphoblastic Leukemia

Purinostat甲磺酸盐是一种独特有效的选择性HDACs抑制剂,用于治疗bcr-abl诱导的b细胞急性淋巴细胞白血病

2019-12-1320
OAAI